These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 22728751)
21. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S; Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve. Bertz RJ; Persson A; Chung E; Zhu L; Zhang J; McGrath D; Grasela D Pharmacotherapy; 2013 Mar; 33(3):284-94. PubMed ID: 23456732 [TBL] [Abstract][Full Text] [Related]
23. PI monotherapy effective as maintenance. AIDS Patient Care STDS; 2005 Oct; 19(10):696. PubMed ID: 16232054 [No Abstract] [Full Text] [Related]
24. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. Sanne I; Piliero P; Squires K; Thiry A; Schnittman S; J Acquir Immune Defic Syndr; 2003 Jan; 32(1):18-29. PubMed ID: 12514410 [TBL] [Abstract][Full Text] [Related]
25. Early virologic rebound in a pilot trial of ritonavir-boosted atanazavir as maintenance monotherapy. Arribas JR; Pulido F J Acquir Immune Defic Syndr; 2007 Sep; 46(1):118; author reply 118-9. PubMed ID: 17909317 [No Abstract] [Full Text] [Related]
26. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation. Winston A; Mallon PW; Satchell C; MacRae K; Williams KM; Schutz M; Law M; Cooper DA; Emery S Clin Infect Dis; 2007 Jun; 44(11):1475-83. PubMed ID: 17479946 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of unboosted atazanavir in combination with lamivudine and didanosine in naive HIV type 1 patients in Senegal. Landman R; Diallo MB; Gueye NF; Kane CT; Mboup S; Fall MB; Ndiaye B; Peytavin G; Bennai Y; Benalycherif A; Girard PM; Sow PS AIDS Res Hum Retroviruses; 2010 May; 26(5):519-25. PubMed ID: 20455760 [TBL] [Abstract][Full Text] [Related]
30. Report from the 13th retrovirus conference. Extending the role of atazanavir. Feinberg J AIDS Clin Care; 2006 Apr; 18(4):38. PubMed ID: 16718882 [No Abstract] [Full Text] [Related]
31. Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study. Mills A; Mildvan D; Podzamczer D; Fätkenheuer G; Leal M; Than S; Valluri SR; Craig C; McFadyen L; Vourvahis M; Heera J; Valdez H; Rinehart AR; Portsmouth S J Acquir Immune Defic Syndr; 2013 Feb; 62(2):164-70. PubMed ID: 23187936 [TBL] [Abstract][Full Text] [Related]